OSR Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kuk Hyoun Hwang
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10900 NE 4th Street Bellevue WA United States of America 98004
- IPO Date
- Mar 21, 2023
- CIK
- 0001840425
- Website
- osr-holdings.com
- Similar Companies
- Business
- OSR Holdings, Inc. is a global healthcare holding company focused on advancing biomedical innovations to improve health and wellness outcomes worldwide. The company develops a diversified portfolio of transformative therapies and healthcare solutions through its subsidiaries, which operate primarily in the United States, Switzerland, and South Korea. Its main products and services include oral immunotherapies for cancer treatment; design-augmented biologics targeting age-related and other degenerative diseases; neurovascular intervention medical device distribution; and noninvasive glucose monitoring technologies. OSR Holdings specializes in immuno-oncology, regenerative biologics, and medical device technologies. The company’s healthcare platforms feature proprietary R&D platforms operated under a hub-and-spoke model that centralizes expertise while allowing subsidiary companies to focus on distinct core competencies, enhancing agility and collaboration. Founded in 2020 and headquartered in Bellevue, Washington, OSR Holdings leverages strategic partnerships and acquisitions to drive innovation and growth. A recent key development includes the strategic acquisition agreement with Woori IO, a South Korean medical device firm specializing in a breakthrough noninvasive glucose monitoring platform. This acquisition positions OSR Holdings as a first mover in the expanding global market for noninvasive glucose monitoring. Additionally, OSR Holdings has appointed Dr. Andreas Niethammer as CEO of its immuno-oncology subsidiary Vaximm AG, underscoring its growth and leadership in the cancer therapeutics pipeline. The company continues evaluating M&A opportunities to expand its healthcare portfolio across the U.S., Europe, and Korea, maintaining full operational and strategic control over its spoke companies. OSR Holdings operates within the healthcare sector focusing on therapeutic development and medical device distribution with a global reach spanning North America, Europe, and Asia. Its business segments include biopharmaceutical innovation through oral T-cell therapeutics targeting tumors; design-augmented biologics for treating degenerative conditions; and the commercialization and distribution of advanced neurovascular medical devices primarily in Korea. The company’s model integrates scientific rigor with responsible corporate stewardship to advance patient-centered healthcare solutions with demonstrated efficacy. OSR Holdings is publicly traded on NASDAQ under the ticker OSRH and actively presents its growth strategy and platform diversification to investors. In summary, OSR Holdings, Inc. is a multifaceted healthcare company advancing immuno-oncology, biologic therapeutics, and medical devices on a global scale through strategic acquisitions and innovative proprietary R&D, with significant recent expansion into noninvasive glucose monitoring and ongoing leadership in cancer treatment development.
Company News
Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
OSR Health, A Message From the CEO
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do
CEO Statement to Shareholders
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
CEO Statement to Shareholders
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026